A functional consequence of this diminished BAFFR expression in ASCs is the inability of the anti-BAFFR antibody used in SLE therapy to impact the survival of bone marrow or splenic plasma cell [52]. This evidence concerns the gene TNFRSF13C and systemic lupus erythematosus.